Aktionärsstruktur

Inhaber in %
Freefloat 99,55
Vanguard Group, Inc. (Subfiler) 8,61
State Street Corp. 5,08
Baker Bros. Advisors LP 4,05
Baker Bros. Advisors LP 4,00
Fidelity Management & Research Co. LLC 3,61
BlackRock Fund Advisors 3,34
ClearBridge Investments LLC 2,92
Vanguard Total Stock Market Index Fund 2,68
BlackRock Institutional Trust Co. NA 2,32
Renaissance Technologies LLC 2,17
Artisan Partners Holdings LP 2,16
Vanguard 500 Index Fund 2,01
Columbia Management Investment Advisers LLC 1,85
Geode Capital Management LLC 1,73

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2016 2017 2018 2019
Personal am Ende des Jahres 3.121 2.525 2.656 3.082
Umsatz pro Mitarbeiter in Mio. EUR 0,96 1,39 1,56 1,61

Bilanz (in Mio. EUR) - Aktiva

2016 2017 2018 2019
Summe Umlaufvermögen 2.578 2.954 3.385 5.076
Summe Anlagevermögen 11.749 11.781 12.372 14.029
Summe Aktiva 13.253 13.583 13.932 17.545

Bilanz (in Mio. EUR) - Passiva

2016 2017 2018 2019
Gesamtverschuldung/ -verbindlichkeiten 3.055 2.888 3.207 2.758
Summe Fremdkapital 4.559 4.690 4.767 6.273
Summe Eigenkapital 8.694 8.893 9.165 11.272
Summe Passiva 13.253 13.583 13.932 17.545

Adresse

121 Seaport Boulevard, 02210 Boston
Telefon +1 (475) 230-2596
Fax +1 (203) 271-8198
Internet http://www.alexion.com

Management

Andreas Rummelt
Independent Director
Aradhana Sarin
President & Director
Becky Lillie
Chief Human Experience Officer
Brian M. Goff
Chief Commercial, Global Operations Officer & EVP
Christopher J. Coughlin
Independent Director
Daniel A. Bazarko
Chief Accounting Officer & Senior Vice President
David Richard Brennan
Chairman
Deborah L. Dunsire
Independent Director
Douglas John Barry
Secretary & Director
Ellen V. Chiniara
Chief Legal Officer & Executive VP
Felix James Baker
Independent Director
Francois Nader
Independent Director
George Llado
Chief Information Officer & Senior Vice President
Gianluca Pirozzi
Head-Clinical Development, Hematology & Nephrology
Indrani M. Franchini
Chief Compliance Officer & Executive VP
John J. Orloff
Executive VP, Head-Research & Development
John T. Mollen
Independent Director
John V. W. Reynders
Vice President-R&D Bioinformatics
Judith A. Reinsdorf
Independent Director
Ludwig N. Hantson
Chief Executive Officer & Director
Michael Ira Kenneth Elloian
Treasurer & Director
Paul A. Friedman
Independent Director
Rana Strellis
SVP-Global Culture & Social Responsibility
Tamar Thompson
Vice President-US Government Affairs & Policy
Tanisha V. Cariño
Chief Corporate Affairs Officer & EVP
Uzair Qadeer
Chief Diversity Officer